{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:47:10Z","timestamp":1794707230292,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3E5E8081191"],"award-info":[{"award-number":["2022M3E5E8081191"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A5A2030333"],"award-info":[{"award-number":["2021R1A5A2030333"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["NS113243"],"award-info":[{"award-number":["NS113243"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormonal regulation during food ingestion and its association with pain prompted the investigation of the impact of glucagon-like peptide-1 (GLP-1) on transient receptor potential vanilloid 1 (TRPV1). Both endogenous and synthetic GLP-1, as well as a GLP-1R antagonist, exendin 9\u201339, reduced heat sensitivity in na\u00efve mice. GLP-1-derived peptides (liraglutide, exendin-4, and exendin 9\u201339) effectively inhibited capsaicin (CAP)-induced currents and calcium responses in cultured sensory neurons and TRPV1-expressing cell lines. Notably, exendin 9\u201339 alleviated CAP-induced acute pain, as well as chronic pain induced by complete Freund\u2019s adjuvant (CFA) and spared nerve injury (SNI), in mice without causing hyperthermia associated with other TRPV1 inhibitors. Electrophysiological analyses revealed that exendin 9\u201339 binds to the extracellular side of TRPV1, functioning as a noncompetitive inhibitor of CAP. Exendin 9\u201339 did not affect proton-induced TRPV1 activation, suggesting its selective antagonism. Among the exendin 9\u201339 fragments, exendin 20\u201329 specifically binds to TRPV1, alleviating pain in both acute and chronic pain models without interfering with GLP-1R function. Our study revealed a novel role for GLP-1 and its derivatives in pain relief, suggesting exendin 20\u201329 as a promising therapeutic candidate.<\/jats:p>","DOI":"10.1038\/s12276-024-01342-8","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T21:02:59Z","timestamp":1730408579000},"page":"2449-2464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-0263","authenticated-orcid":false,"given":"Eun Jin","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Min","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Mahbubur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeik","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn Yi","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Gil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunJae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temugin","family":"Berta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4152-3022","authenticated-orcid":false,"given":"Chul-Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pmrj.2013.08.597","volume":"6","author":"AL Meleger","year":"2014","unstructured":"Meleger, A. L., Froude, C. K. & Walker, J. 3rd. Nutrition and eating behavior in patients with chronic pain receiving long-term opioid therapy. PM R. 6, 7\u201312.e11 (2014).","journal-title":"PM R."},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/oby.2012.39","volume":"20","author":"E Amy Janke","year":"2012","unstructured":"Amy Janke, E. & Kozak, A. T. \u201cThe more pain I have, the more I want to eat\u201d: obesity in the context of chronic pain. Obesity 20, 2027\u20132034 (2012).","journal-title":"Obesity"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"16865","DOI":"10.1073\/pnas.0506226102","volume":"102","author":"H Foo","year":"2005","unstructured":"Foo, H. & Mason, P. Sensory suppression during feeding. Proc. Natl Acad. Sci. USA 102, 16865\u201316869 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1152\/jn.1983.50.6.1497","volume":"50","author":"KL Casey","year":"1983","unstructured":"Casey, K. L. & Morrow, T. J. Nocifensive responses to cutaneous thermal stimuli in the cat: stimulus-response profiles, latencies, and afferent activity. J. Neurophysiol. 50, 1497\u20131515 (1983).","journal-title":"J. Neurophysiol."},{"key":"1342_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0031-9384(98)00020-1","volume":"64","author":"LM Wylie","year":"1998","unstructured":"Wylie, L. M. & Gentle, M. J. Feeding-induced tonic pain suppression in the chicken: reversal by naloxone. Physiol. Behav. 64, 27\u201330 (1998).","journal-title":"Physiol. Behav."},{"key":"1342_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.physbeh.2009.03.015","volume":"97","author":"H Foo","year":"2009","unstructured":"Foo, H., Crabtree, K., Thrasher, A. & Mason, P. Eating is a protected behavior even in the face of persistent pain in male rats. Physiol. Behav. 97, 426\u2013429 (2009).","journal-title":"Physiol. Behav."},{"key":"1342_CR7","doi-asserted-by":"publisher","first-page":"13053","DOI":"10.1523\/JNEUROSCI.3514-09.2009","volume":"29","author":"H Foo","year":"2009","unstructured":"Foo, H. & Mason, P. Analgesia accompanying food consumption requires ingestion of hedonic foods. J. Neurosci. 29, 13053\u201313062 (2009).","journal-title":"J. Neurosci."},{"key":"1342_CR8","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1172\/JCI43766","volume":"120","author":"MH Ossipov","year":"2010","unstructured":"Ossipov, M. H., Dussor, G. O. & Porreca, F. Central modulation of pain. J. Clin. Invest. 120, 3779\u20133787 (2010).","journal-title":"J. Clin. Invest."},{"key":"1342_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1210\/edrv-16-3-390","volume":"16","author":"HC Fehmann","year":"1995","unstructured":"Fehmann, H. C., Goke, R. & Goke, B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16, 390\u2013410 (1995).","journal-title":"Endocr. Rev."},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.2337\/db06-S020","volume":"55","author":"GE Lim","year":"2006","unstructured":"Lim, G. E. & Brubaker, P. L. Glucagon-like peptide 1 secretion by the L-cell\u2014the view from within. Diabetes 55, S70\u2013S77 (2006).","journal-title":"Diabetes"},{"key":"1342_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1074\/jbc.M109.033829","volume":"285","author":"CR Underwood","year":"2010","unstructured":"Underwood, C. R. et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723\u2013730 (2010).","journal-title":"J. Biol. Chem."},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","volume":"100","author":"E Brown","year":"2018","unstructured":"Brown, E., Cuthbertson, D. J. & Wilding, J. P. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides 100, 61\u201367 (2018).","journal-title":"Peptides"},{"key":"1342_CR13","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","volume":"34","author":"N Gong","year":"2014","unstructured":"Gong, N. et al. Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J. Neurosci. 34, 5322\u20135334 (2014).","journal-title":"J. Neurosci."},{"key":"1342_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.phrs.2015.10.008","volume":"102","author":"Y Jia","year":"2015","unstructured":"Jia, Y., Gong, N., Li, T. F., Zhu, B. & Wang, Y. X. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor\/beta-endorphin pathway. Pharm. Res. 102, 276\u2013285 (2015).","journal-title":"Pharm. Res."},{"key":"1342_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/cns.13694","volume":"27","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Spinal microglial beta-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain. CNS Neurosci. Ther. 27, 1157\u20131172 (2021).","journal-title":"CNS Neurosci. Ther."},{"key":"1342_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/biof.1406","volume":"44","author":"C Rebosio","year":"2018","unstructured":"Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R. & Fedele, E. Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus. Biofactors 44, 148\u2013157 (2018).","journal-title":"Biofactors"},{"key":"1342_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1124\/mol.116.107102","volume":"91","author":"HY Wu","year":"2017","unstructured":"Wu, H. Y., Mao, X. F., Fan, H. & Wang, Y. X. p38beta Mitogen- activated protein kinase signaling mediates exenatide-stimulated microglial beta-endorphin expression. Mol. Pharm. 91, 451\u2013463 (2017).","journal-title":"Mol. Pharm."},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1523\/JNEUROSCI.1799-17.2017","volume":"37","author":"HY Wu","year":"2017","unstructured":"Wu, H. Y., Tang, X. Q., Mao, X. F. & Wang, Y. X. Autocrine interleukin-10 mediates glucagon-like peptide-1 receptor-induced spinal microglial beta-endorphin expression. J. Neurosci. 37, 11701\u201311714 (2017).","journal-title":"J. Neurosci."},{"key":"1342_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1126\/science.288.5464.306","volume":"288","author":"MJ Caterina","year":"2000","unstructured":"Caterina, M. J. et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306\u2013313 (2000).","journal-title":"Science"},{"key":"1342_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41573-021-00268-4","volume":"21","author":"AP Koivisto","year":"2022","unstructured":"Koivisto, A. P., Belvisi, M. G., Gaudet, R. & Szallasi, A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat. Rev. Drug Discov. 21, 41\u201359 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0304-3959(02)00067-2","volume":"99","author":"T Fukuoka","year":"2002","unstructured":"Fukuoka, T. et al. VR1, but not P2X(3), increases in the spared L4 DRG in rats with L5 spinal nerve ligation. Pain 99, 111\u2013120 (2002).","journal-title":"Pain"},{"key":"1342_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.neuropharm.2005.05.003","volume":"49","author":"Y Kanai","year":"2005","unstructured":"Kanai, Y., Nakazato, E., Fujiuchi, A., Hara, T. & Imai, A. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology 49, 977\u2013984 (2005).","journal-title":"Neuropharmacology"},{"key":"1342_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1211\/jpp.60.6.0006","volume":"60","author":"W Yamamoto","year":"2008","unstructured":"Yamamoto, W., Sugiura, A., Nakazato-Imasato, E. & Kita, Y. Characterization of primary sensory neurons mediating static and dynamic allodynia in rat chronic constriction injury model. J. Pharm. Pharm. 60, 717\u2013722 (2008).","journal-title":"J. Pharm. Pharm."},{"key":"1342_CR24","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1523\/JNEUROSCI.4833-06.2007","volume":"27","author":"NR Gavva","year":"2007","unstructured":"Gavva, N. R. et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci. 27, 3366\u20133374 (2007).","journal-title":"J. Neurosci."},{"key":"1342_CR25","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1523\/JNEUROSCI.1483-07.2007","volume":"27","author":"AA Steiner","year":"2007","unstructured":"Steiner, A. A. et al. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci. 27, 7459\u20137468 (2007).","journal-title":"J. Neurosci."},{"key":"1342_CR26","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1021\/jm0495071","volume":"48","author":"DM Swanson","year":"2005","unstructured":"Swanson, D. M. et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48, 1857\u20131872 (2005).","journal-title":"J. Med. Chem."},{"key":"1342_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pain.2008.01.024","volume":"136","author":"NR Gavva","year":"2008","unstructured":"Gavva, N. R. et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136, 202\u2013210 (2008).","journal-title":"Pain"},{"key":"1342_CR28","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1097\/PR9.0000000000000576","volume":"1","author":"P Manitpisitkul","year":"2016","unstructured":"Manitpisitkul, P. et al. TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study. Pain. Rep. 1, e576 (2016).","journal-title":"Pain. Rep."},{"key":"1342_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1365-2125.2012.04405.x","volume":"75","author":"AA Othman","year":"2013","unstructured":"Othman, A. A., Nothaft, W., Awni, W. M. & Dutta, S. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic\/pharmacodynamic analysis of three phase 1 trials. Br. J. Clin. Pharm. 75, 1029\u20131040 (2013).","journal-title":"Br. J. Clin. Pharm."},{"key":"1342_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1365-2125.2011.04040.x","volume":"72","author":"P Round","year":"2011","unstructured":"Round, P., Priestley, A. & Robinson, J. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br. J. Clin. Pharm. 72, 921\u2013931 (2011).","journal-title":"Br. J. Clin. Pharm."},{"key":"1342_CR31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.pain.2011.01.051","volume":"152","author":"MC Rowbotham","year":"2011","unstructured":"Rowbotham, M. C. et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 152, 1192\u20131200 (2011).","journal-title":"Pain"},{"key":"1342_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13038","volume":"223","author":"A Garami","year":"2018","unstructured":"Garami, A. et al. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds\u2019 pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. Acta Physiol. 223, e13038 (2018).","journal-title":"Acta Physiol."},{"key":"1342_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1124\/jpet.107.132233","volume":"326","author":"SG Lehto","year":"2008","unstructured":"Lehto, S. G. et al. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J. Pharm. Exp. Ther. 326, 218\u2013229 (2008).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1342_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neuroscience.2008.06.069","volume":"156","author":"C Mills","year":"2008","unstructured":"Mills, C. et al. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. Neuroscience 156, 165\u2013174 (2008).","journal-title":"Neuroscience"},{"key":"1342_CR35","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1523\/JNEUROSCI.5150-09.2010","volume":"30","author":"A Garami","year":"2010","unstructured":"Garami, A. et al. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J. Neurosci. 30, 1435\u20131440 (2010).","journal-title":"J. Neurosci."},{"key":"1342_CR36","doi-asserted-by":"publisher","first-page":"15854","DOI":"10.3390\/ijms232415854","volume":"23","author":"MM Rahman","year":"2022","unstructured":"Rahman, M. M., Jo, H. J., Park, C. K. & Kim, Y. H. Diosgenin exerts analgesic effects by antagonizing the selective inhibition of transient receptor potential vanilloid 1 in a mouse model of neuropathic pain. Int. J. Mol. Sci. 23, 15854 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1342_CR37","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","volume":"287","author":"JJ Holst","year":"2004","unstructured":"Holst, J. J. & Gromada, J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab. 287, E199\u2013E206 (2004).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1342_CR38","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1172\/JCI1349","volume":"101","author":"J Schirra","year":"1998","unstructured":"Schirra, J. et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest. 101, 1421\u20131430 (1998).","journal-title":"J. Clin. Invest."},{"key":"1342_CR39","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","volume":"53","author":"CF Deacon","year":"2004","unstructured":"Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53, 2181\u20132189 (2004).","journal-title":"Diabetes"},{"key":"1342_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1124\/jpet.102.045674","volume":"306","author":"KJ Valenzano","year":"2003","unstructured":"Valenzano, K. J. et al. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J. Pharm. Exp. Ther. 306, 377\u2013386 (2003).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1342_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1124\/jpet.107.125674","volume":"323","author":"NR Gavva","year":"2007","unstructured":"Gavva, N. R. et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharm. Exp. Ther. 323, 128\u2013137 (2007).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1342_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107474","volume":"208","author":"A Garami","year":"2020","unstructured":"Garami, A. et al. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis. Pharm. Ther. 208, 107474 (2020).","journal-title":"Pharm. Ther."},{"key":"1342_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00001756-200403220-00016","volume":"15","author":"H Luo","year":"2004","unstructured":"Luo, H., Cheng, J., Han, J. S. & Wan, Y. Change of vanilloid receptor 1 expression in dorsal root ganglion and spinal dorsal horn during inflammatory nociception induced by complete Freund\u2019s adjuvant in rats. Neuroreport 15, 655\u2013658 (2004).","journal-title":"Neuroreport"},{"key":"1342_CR44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jpain.2009.09.018","volume":"11","author":"D Vilceanu","year":"2010","unstructured":"Vilceanu, D., Honore, P., Hogan, Q. H. & Stucky, C. L. Spinal nerve ligation in mouse upregulates TRPV1 heat function in injured IB4-positive nociceptors. J. Pain. 11, 588\u2013599 (2010).","journal-title":"J. Pain."},{"key":"1342_CR45","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1124\/mol.105.015727","volume":"68","author":"NR Gavva","year":"2005","unstructured":"Gavva, N. R. et al. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol. Pharm. 68, 1524\u20131533 (2005).","journal-title":"Mol. Pharm."},{"key":"1342_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173443","volume":"885","author":"T Sedman","year":"2020","unstructured":"Sedman, T., Krass, M., Runkorg, K., Vasar, E. & Volke, V. Tolerance develops toward GLP-1 receptor agonists\u2019 glucose-lowering effect in mice. Eur. J. Pharm. 885, 173443 (2020).","journal-title":"Eur. J. Pharm."},{"key":"1342_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pbb.2013.12.002","volume":"117","author":"RT Yamamoto","year":"2014","unstructured":"Yamamoto, R. T., Foulds-Mathes, W. & Kanarek, R. B. Antinociceptive actions of peripheral glucose administration. Pharm. Biochem. Behav. 117, 34\u201339 (2014).","journal-title":"Pharm. Biochem. Behav."},{"key":"1342_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/35012076","volume":"405","author":"JB Davis","year":"2000","unstructured":"Davis, J. B. et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183\u2013187 (2000).","journal-title":"Nature"},{"key":"1342_CR49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","volume":"33","author":"S Mercadante","year":"2019","unstructured":"Mercadante, S., Arcuri, E. & Santoni, A. Opioid- induced tolerance and hyperalgesia. CNS Drugs 33, 943\u2013955 (2019).","journal-title":"CNS Drugs"},{"key":"1342_CR50","doi-asserted-by":"publisher","first-page":"eaaw6471","DOI":"10.1126\/scitranslmed.aaw6471","volume":"12","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci. Transl. Med. 12, eaaw6471 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1342_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd2280","volume":"6","author":"A Szallasi","year":"2007","unstructured":"Szallasi, A., Cortright, D. N., Blum, C. A. & Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6, 357\u2013372 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1342_CR52","doi-asserted-by":"publisher","first-page":"e0141921","DOI":"10.1371\/journal.pone.0141921","volume":"10","author":"S Fujita","year":"2015","unstructured":"Fujita, S. et al. Exenatide facilitates recovery from oxaliplatin-induced peripheral neuropathy in rats. PLoS ONE 10, e0141921 (2015).","journal-title":"PLoS ONE"},{"key":"1342_CR53","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2337\/db10-1462","volume":"60","author":"T Himeno","year":"2011","unstructured":"Himeno, T. et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 60, 2397\u20132406 (2011).","journal-title":"Diabetes"},{"key":"1342_CR54","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/NEN.0b013e3182580673","volume":"71","author":"M Kan","year":"2012","unstructured":"Kan, M., Guo, G., Singh, B., Singh, V. & Zochodne, D. W. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J. Neuropathol. Exp. Neurol. 71, 494\u2013510 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1342_CR55","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/j.1476-5381.2011.01272.x","volume":"164","author":"WJ Liu","year":"2011","unstructured":"Liu, W. J. et al. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats. Br. J. Pharm. 164, 1410\u20131420 (2011).","journal-title":"Br. J. Pharm."},{"key":"1342_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0896-6273(02)00908-X","volume":"36","author":"RR Ji","year":"2002","unstructured":"Ji, R. R., Samad, T. A., Jin, S. X., Schmoll, R. & Woolf, C. J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36, 57\u201368 (2002).","journal-title":"Neuron"},{"key":"1342_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-61","volume":"4","author":"L Yu","year":"2008","unstructured":"Yu, L. et al. The role of TRPV1 in different subtypes of dorsal root ganglion neurons in rat chronic inflammatory nociception induced by complete Freund\u2019s adjuvant. Mol. Pain. 4, 61 (2008).","journal-title":"Mol. Pain."},{"key":"1342_CR58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13238-016-0353-7","volume":"8","author":"F Yang","year":"2017","unstructured":"Yang, F. & Zheng, J. Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. Protein Cell 8, 169\u2013177 (2017).","journal-title":"Protein Cell"},{"key":"1342_CR59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0304-3940(01)02093-6","volume":"310","author":"SM Carlton","year":"2001","unstructured":"Carlton, S. M. & Coggeshall, R. E. Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. Neurosci. Lett. 310, 53\u201356 (2001).","journal-title":"Neurosci. Lett."},{"key":"1342_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137397","volume":"812","author":"F Jing","year":"2023","unstructured":"Jing, F., Zou, Q. & Pu, Y. GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neurosci. Lett. 812, 137397 (2023).","journal-title":"Neurosci. Lett."},{"key":"1342_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01631-z","volume":"24","author":"N Krajnc","year":"2023","unstructured":"Krajnc, N. et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J. Headache Pain. 24, 89 (2023).","journal-title":"J. Headache Pain."},{"key":"1342_CR62","doi-asserted-by":"publisher","first-page":"G23","DOI":"10.1152\/ajpgi.00189.2019","volume":"319","author":"F Mayer","year":"2020","unstructured":"Mayer, F., Gunawan, A. L., Tso, P. & Aponte, G. W. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves. Am. J. Physiol. Gastrointest. Liver Physiol. 319, G23\u2013G35 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1342_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2022.170749","volume":"151","author":"A Mayendraraj","year":"2022","unstructured":"Mayendraraj, A., Rosenkilde, M. M. & Gasbjerg, L. S. GLP-1 and GIP receptor signaling in beta cells\u2014a review of receptor interactions and co-stimulation. Peptides 151, 170749 (2022).","journal-title":"Peptides"},{"key":"1342_CR64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1342_CR65","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1016\/j.cell.2021.08.012","volume":"184","author":"K Zhang","year":"2021","unstructured":"Zhang, K., Julius, D. & Cheng, Y. Structural snapshots of TRPV1 reveal mechanism of polymodal functionality. Cell 184, 5138\u20135150.e5112 (2021).","journal-title":"Cell"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-024-01342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-024-01342-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-024-01342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:02:42Z","timestamp":1733097762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-024-01342-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1038\/s12276-024-01342-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4233732\/v1","asserted-by":"object"}]},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}